ArticleMolecular medicine reports2017
Astragaloside IV protects against apoptosis in human degenerative chondrocytes through autophagy activation.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The dual role of autophagy in cartilage degradation: from mechanisms to targeted therapeutics.Frontiers in cell and developmental biology · 2026Review
- Astragaloside IV Alleviates Osteoarthritis by Upregulating ETS2: A Bioinformatics and Experimental Study.Journal of inflammation research · 2026Article
- Exploring the mechanism of action of astragaloside in the treatment of osteoarthritis based on network pharmacology.Biomedical engineering online · 2025Article
- Astragaloside IV attenuates glucocorticoid-induced osteoclastogenesis and bone loss via the MAPK/NF-κB pathway.BMC complementary medicine and therapies · 2025Article
- Astragaloside IV Protects Against Podocyte Injury by Upregulating Mitophagy via Mfn2/Pink1/Parkin Axis.Current molecular medicine · 2025Article
- Astragaloside IV reduces mutant Ataxin-3 levels and supports mitochondrial function in Spinocerebellar Ataxia Type 3.Scientific reports · 2024Article
- Autophagy in Osteoarthritis: A Double-Edged Sword in Cartilage Aging and Mechanical Stress Response: A Systematic Review.Journal of clinical medicine · 2024Review
- Astragaloside IV Protects Against IL-1β-Induced Chondrocyte DamageCurrent molecular medicine · 2024Article
- Role of Autophagy Mediated by AMPK/DDiT4/mTOR Axis in HT22 Cells Under Oxygen and Glucose Deprivation/Reoxygenation.ACS omega · 2023Article
- Astragaloside IV attenuates IL-1β-induced intervertebral disc degeneration through inhibition of the NF-κB pathway.Journal of orthopaedic surgery and research · 2022Article
- Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation.World journal of clinical cases · 2022Review
- Autophagy: An important target for natural products in the treatment of bone metabolic diseases.Frontiers in pharmacology · 2022Review
- New insights into the interplay between autophagy and cartilage degeneration in osteoarthritis.Frontiers in cell and developmental biology · 2022Review
- Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function.Frontiers in cell and developmental biology · 2021Article
- Phytochemicals Mediate Autophagy Against Osteoarthritis by Maintaining Cartilage Homeostasis.Frontiers in pharmacology · 2021Review
- Research Progress on the Antiosteoarthritic Mechanism of Action of Natural Products.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Astragaloside IV protects ATDC5 cells from lipopolysaccharide-caused damage through regulating miR-203/MyD88.Pharmaceutical biology · 2020Article
- Article
- Recent advance in treatment of osteoarthritis by bioactive components from herbal medicine.Chinese medicine · 2020Review
- Jianpiyifei II Granules Suppress Apoptosis of Bronchial Epithelial Cells in Chronic Obstructive Pulmonary DiseaseFrontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased cell apoptosis in chondrocytes is a feature of degenerative cartilage. Astragaloside IV (AST) has been proven to possess an antiarthritic effect by preventing interleukin (IL)‑1β‑induced cartilage damage. However, the role of AST on chondrocyte apoptosis and its underlying mechanism remains unknown. In the present study, degenerative chondrocytes isolated from patients with osteoarthritis (OA) were subjected to AST and IL‑1β treatment. Results indicated that AST protected against chondrocyte apoptosis induced by IL‑1β. Western blotting indicated that AST increased the protein expression of LC3‑II/I and decreased P62/SQSTM1 expression, which suggested that AST upregulated autophagy activity in chondrocytes. Fluorescent protein GFP‑LC3 analysis and transmission electron microscopy observation confirmed that autophagy was promoted by AST. In contrast, after autophagy inhibited by 3‑methyladenine, chondrocyte apoptosis was further increased under IL‑1β treatment. Ultimately, rapamycin was used as a positive control, whose results confirmed that rapamycin‑mediated autophagy also decreased chondrocyte apoptosis induced by IL‑1β. In conclusion, these results suggested that AST‑mediated autophagy serves an anti‑apoptotic role in chondrocytes, which may aid the development of novel therapeutic approaches for OA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.